Literature DB >> 23730311

Serological survey of the novel influenza A H1N1 in inner city Winnipeg, Manitoba, 2009.

Laura H Thompson1, Salaheddin M Mahmud, Yoav Keynan, James F Blanchard, Joyce Slater, Magdy Dawood, Keith Fowke, Paul Van Caeseele, Marissa Becker.   

Abstract

INTRODUCTION: Little is known about the determinants of pandemic H1N1 (pH1N1) infection in Canada among low-income, inner city populations. To inform future influenza planning, the seroprevalence of pH1N1 antibodies among inner city clinic attendees in Winnipeg (Manitoba) according to sociodemographic and risk factor characteristics were estimated and vaccination rates were explored.
METHODS: Adults presenting to three inner city community clinics in Winnipeg from October 2009 to December 2009 were recruited as study participants (n=458). A questionnaire was administered to collect demographic, risk factor and symptom information, and a venous blood sample was collected for hemagglutination inhibition assay testing to detect the presence of antibodies against pH1N1.
RESULTS: Approximately one-half (53%) of the study participants reported an annual household income of <$10,000/year, and 65% identified as Aboriginal. pH1N1 positivity was 5.7% among those enrolled early in the study and 15.5% among those enrolled later in the study. Positivity was higher among participants who were female, Aboriginal and in contact with children ≤5 years of age. The overall pH1N1 vaccination rate was 28%. DISCUSSION: pH1N1 positivity was high among low-income adults accessing clinics in Winnipeg's inner city compared with the general population. Of further concern were the low rates of uptake of both seasonal and pH1N1 influenza vaccinations. When planning for future influenza outbreaks, it is important to incorporate strategies for the prevention, control, and care of influenza among low-income and inner city adults.

Entities:  

Keywords:  Epidemiology; Hemagglutination inhibition assay; Inner city; Pandemic Influenza A H1N1; Serological survey; pH1N1

Year:  2012        PMID: 23730311      PMCID: PMC3403663          DOI: 10.1155/2012/484693

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  18 in total

1.  Estimated cumulative incidence of pandemic (H1N1) influenza among pregnant women during the first wave of the 2009 pandemic.

Authors:  Salaheddin M Mahmud; Marissa Becker; Yoav Keynan; Lawrence Elliott; Laura H Thompson; Keith Fowke; Lisa Avery; Paul Van Caeseele; Sande Harlos; James Blanchard; Magdy Dawood
Journal:  CMAJ       Date:  2010-09-07       Impact factor: 8.262

Review 2.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

3.  Trends in influenza vaccination in Canada, 1996/1997 to 2005.

Authors:  Jeff C Kwong; Laura C Rosella; Helen Johansen
Journal:  Health Rep       Date:  2007-11       Impact factor: 4.796

4.  The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific.

Authors:  G La Ruche; A Tarantola; P Barboza; L Vaillant; J Gueguen; M Gastellu-Etchegorry
Journal:  Euro Surveill       Date:  2009-10-22

Review 5.  Determinants of immunity to influenza infection in man.

Authors:  C W Potter; J S Oxford
Journal:  Br Med Bull       Date:  1979-01       Impact factor: 4.291

6.  Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial.

Authors:  Mark Loeb; Margaret L Russell; Lorraine Moss; Kevin Fonseca; Julie Fox; David J D Earn; Fred Aoki; Gregory Horsman; Paul Van Caeseele; Khami Chokani; Mark Vooght; Lorne Babiuk; Richard Webby; Stephen D Walter
Journal:  JAMA       Date:  2010-03-10       Impact factor: 56.272

Review 7.  Pandemic 2009 (A)H1N1 influenza (swine flu) - the Manitoba experience.

Authors:  Joanne Embree
Journal:  Biochem Cell Biol       Date:  2010-08       Impact factor: 3.626

Review 8.  Haemagglutination-inhibiting antibody to influenza virus.

Authors:  J C de Jong; A M Palache; W E P Beyer; G F Rimmelzwaan; A C M Boon; A D M E Osterhaus
Journal:  Dev Biol (Basel)       Date:  2003

9.  Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-05-22       Impact factor: 17.586

10.  Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

Authors:  Matthew R Sandbulte; Gretchen S Jimenez; Adrianus C M Boon; Larry R Smith; John J Treanor; Richard J Webby
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

View more
  2 in total

1.  Comparison of the epidemiology of laboratory-confirmed influenza A and influenza B cases in Manitoba, Canada.

Authors:  Aynslie M Hinds; Songul Bozat-Emre; Paul Van Caeseele; Salaheddin M Mahmud
Journal:  BMC Public Health       Date:  2015-01-30       Impact factor: 3.295

2.  Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?

Authors:  Salaheddin M Mahmud; Songul Bozat-Emre; Gregory Hammond; Lawrence Elliott; Paul Van Caeseele
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.